Novel ruthenium amide conjugates as potential anticancer compounds (CROSBI ID 688512)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa
Podaci o odgovornosti
Opačak, Saša ; Landais, Corentin ; Pernar, Margareta ; Brozović, Anamarija ; Kirin, Srećko
engleski
Novel ruthenium amide conjugates as potential anticancer compounds
Cancer is the second leading cause of death globally accounting for one out of six disease related deaths.[1] Platinum drugs are most commonly applied in cancer treatment but exhibit numerous side effects. [2] In order to mitigate these side effect ruthenium organometallics have been developed as promising alternatives. Although no ruthenium compounds are currently in clinical usage, a number of compounds show superior properties over platinumbased drugs. [3] In our previous work [4] ruthenium(II) complexes of amino acid phosphine bioconjugates have shown relevant cytotoxic activity with selectivity towards tumour cells. Herein, we expand this work and present derivatives 1 and 2 (Fig 1) with one formally isomerised amide bond, inspired by our enantioselective catalysts. [5] The newly synthesised compounds were characterised by various spectroscopic methods and their biological properties were explored in HeLa cells
Ruthenium ; amide ; cancer ; hella cells
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
175-175.
2020.
objavljeno
Podaci o matičnoj publikaciji
Knjige sažetaka (SMLKI)
Dejanović, Igor ; Vrsaljko, Domagoj ; Žižek, Krunoslav
Zagreb: Hrvatsko društvo kemijskih inženjera i tehnologa (HDKI)
978-953-6894-71-0
Podaci o skupu
XIII. susret mladih kemijskih inženjera (SMLKI 2020)
poster
20.02.2020-21.02.2020
Zagreb, Hrvatska